



Article

Toxicokinetics of Hydrolyzed Fumonisin B₁ After Single Oral or Intravenous Bolus to Broiler Chickens Fed a Control or a Fumonisin-Contaminated Diet

Gunther Antonissen ^{1,2,*}, Siegrid De Baere ¹, Barbara Novak ³, Dian Schatzmayr ³,
Danica den Hollander ¹, Mathias Devreese ¹ and Siska Croubels ¹

¹ Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium; Siegrid.DeBaere@ugent.be (S.D.B.); Danica.denHollander@ugent.be (D.d.H.); Mathias.Devreese@ugent.be (M.D.); Siska.Croubels@ugent.be (S.C.)

² Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium

³ Biomin Research Center, Technopark 1, 3430 Tulln, Austria; Barbara.Novak@biomin.net (B.N.); Dian.Schatzmayr@biomin.net (D.S.)

* Correspondence: Gunther.Antonissen@UGent.be; Tel.: +32-9-264-7486

Received: 18 May 2020; Accepted: 18 June 2020; Published: 21 June 2020

Abstract: The toxicokinetics (TK) of hydrolyzed fumonisin B₁ (HFB₁) were evaluated in 16 broiler chickens after being fed either a control or a fumonisin-contaminated diet (10.8 mg fumonisin B₁, 3.3 mg B₂ and 1.5 mg B₃/kg feed) for two weeks, followed by a single oral (PO) or intravenous (IV) dose of 1.25 mg/kg bodyweight (BW) of HFB₁. Fumonisin B₁ (FB₁), its partially hydrolyzed metabolites pHFB_{1a} and pHFB_{1b}, and fully hydrolyzed metabolite HFB₁, were determined in chicken plasma using a validated ultra-performance liquid chromatography–tandem mass spectrometry method. None of the broiler chicken showed clinical symptoms of fumonisins (FBs) or HFB₁ toxicity during the trial, nor was an aberration in body weight observed between the animals fed the FBs-contaminated diet and those fed the control diet. HFB₁ was shown to follow a two-compartmental pharmacokinetic model with first order elimination in broiler chickens after IV administration. Toxicokinetic parameters of HFB₁ demonstrated a total body clearance of 16.39 L/kg·h and an intercompartmental flow of 8.34 L/kg·h. Low levels of FB₁ and traces of pHFB_{1b} were found in plasma of chickens fed the FBs-contaminated diet. Due to plasma concentrations being under the limit of quantification (LOQ) after oral administration of HFB₁, no toxicokinetic modelling could be performed in broiler chickens after oral administration of HFB₁. Moreover, no phase II metabolites, nor N-acyl-metabolites of HFB₁ could be detected in this study.

Keywords: mycotoxins; toxicokinetics; fumonisin metabolites; feeding trial; broiler chicken

Key Contribution: For the first time toxicokinetic parameters of hydrolyzed fumonisin B₁ (HFB₁) were calculated in broiler chicken, after a feeding trial of a control or a fumonisin B₁ contaminated diet and followed by a single oral or intravenous bolus of HFB₁.

1. Introduction

Fumonisin (FBs) are secondary fungal metabolites of *Fusarium verticillioides*, *F. proliferatum* or other *Fusarium* species, that resemble each other structurally [1,2]. Fumonisin B₁ (FB₁), B₂ (FB₂) and B₃ (FB₃) represent the most important of the more than 15 FBs analogues that have been described [3]. FBs can be divided into four main categories, namely A, B, C and P [4]. Since FB₁ is the most prevalent

and toxic analogue, toxicological assessment of FBs has mostly been done for FB₁. FB₁ is a diester of propane-1,2,3-tricarboxylic acid (TCA), which has a long aminopolyol side-chain, namely 2-amino-12,16-dimethyl-3,5,10,14,15-pentahydroxyeicosane [3]. FB₂ and FB₃ differ structurally from FB₁ in the number and position of hydroxyl groups, since a free hydroxyl group is lacking on either the C-10 or the C-5 position, as shown in Figure 1 [2]. The primary amino group is known for the biological activity of FBs, as acetylation of FB₁ to fumonisins A₁ hampers the cytotoxicity as well as the inhibition of ceramide synthase [3].




Figure 1. Structures of the fumonisins FB₁, FB₂ and FB₃ with tricarballic acid side-chains (TCA), and of the hydrolyzed fumonisins HFB₁ and HFB₂ (or aminopentols, AP₁ and AP₂, respectively) and the corresponding N-acyl-derivatives [5]. Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

FBs reveal distinct structural similarities to sphingolipids, due to their long-chain base backbones. Hence, FBs have the ability to completely inhibit sphinganine N-acyl transferase (ceramide synthase), resulting in a disruption of the ceramide and sphingolipid metabolism [6–8]. Blockage of the ceramide synthase enzyme not only leads to the inhibition of sphingolipids synthesis, but also induces an accumulation of free sphinganine (Sa) and sphingosine (So) in tissues, serum and urine [2,4]. This associated increase of the Sa:So ratio, observed in tissues and body fluids after exposure to FBs, is a suitable biomarker of effect in animals and humans [2,9,10]. In most animal species, the liver, as well as the kidneys and the intestinal tract, are the main target organs of FBs toxicity [2,11,12]. Generally, poultry are rather resistant to FBs in comparison to mammals, especially pigs and horses [13–18]. Only during the first three days of life (≥ 125 mg/kg feed) was an increase in mortality after FB₁ exposure observed in broiler chickens [13], as well as in growing ducks aged 12–14 weeks (20 mg/kg feed) [16]. Feeding a FB₁-contaminated diet (100–400 mg/kg feed) to broilers resulted in black, sticky diarrhea in the first 2 weeks of life [15]. Besides, broiler chickens fed an FBs-contaminated diet in doses from 100 to 400 mg FB₁/kg feed for 2 to 3 weeks showed a dose-dependent decrease in feed intake and bodyweight gain [13,15]. No negative effects on performance were observed under experimental conditions, at concentration levels which were below or approached

the European maximum guidance level in feed (20 mg FB₁ + FB₂/kg feed) [19]. However, it was recently demonstrated that even low to moderate dietary levels of FBs negatively affect enterocyte viability and proliferation, and the production of pro-inflammatory cytokines, and alter the intestinal barrier function, and therefore increase the susceptibility of avian species to important enteric infectious diseases, such as coccidiosis and necrotic enteritis [20–23]. Furthermore, the mRNA expression of genes encoding for the intestinal cytochrome P450 (CYP450), the drug-metabolizing enzyme CYP1A4, and the drug transporter mechanisms, such as multiple drug resistance protein 1 (MDR1 or P-glycoprotein, P-gp), in broiler chickens were upregulated following exposure to 25 mg FB₁ + FB₂/kg feed for 15 days, which can affect the pharmacokinetic (PK) or toxicokinetic (TK) properties of other xenobiotics substrates [24].

Therefore, taking into account that mycotoxin contamination of feed is a continuous feed safety issue, resulting in economic losses during animal production [25], methods for the detoxification of feed have been developed. For FBs, these imply feed processing techniques, such as alkaline cooking (nixtamalization) used during the production of masa and tortillas for human consumption, and the application of mycotoxin binders/modifiers in animal feed. Mycotoxin binders, such as clays, are highly effective against aflatoxins, however, their detoxification capacity with regards to FBs is rather limited. In contrast, following the application of FB esterase FumD (EC 3.1.1.87), enzymatic degradation results in conversion of FBs to the less toxic partially hydrolyzed FB₁ (pHFB₁), or fully hydrolyzed HFB₁, by cleavage of the tricarballic acid esters at the C-14 and/or C-15 position. FB esterase FumD is an enzyme of bacterial FB catabolism [26,27], which has recently been commercialized as FUMzyme® (BIOMIN GmbH, Getzersdorf, Austria) and authorized by the EU for usage in poultry and pigs. Enzymatic hydrolysis has been shown to be an effective detoxification method in broilers, since it prevents the FB-associated disruption of the sphingolipid metabolism, characterized by a reduced serum and hepatic Sa:So ratio and a counteracting FB-induced intestinal up-regulation of cytokine gene expression [interleukin-8 (IL-8) and IL-10] [28]. Besides, in accordance with different mammalian species [29–31], it has been demonstrated that the intestinal microbiota of broiler chickens and turkeys also has a limited capacity to hydrolyze FBs [28,32].

The only known metabolic pathway of FB₁ is the hydrolyzation (hydrolysis) of its side-chains in vertebrates [11]. HFB₁ is not only a 10-fold less potent inhibitor of ceramide synthase than FB₁, but it is also a substrate for ceramide synthase in rat liver microsomes [5,26,31,33,34]. Acetylation of HFB₁ at the primary amino group, with fatty acids of variable chain lengths, results in the formation of N-acetyl-HFB₁ (NAHFB₁) metabolites, which are also known to be ceramide analogues. The in vivo formation of NAHFB₁ has been demonstrated in rats [5]. Furthermore, phase II conjugation processes of FB₁, e.g., sulphatation as proposed by Hopmans et al. (1997) [35], or glucuronidation, have not yet been identified. However, no data are available on the in vivo TK of HFB₁, nor on the formation of NAHFB₁ in chickens [36]. Furthermore, FB₁ is not absorbed in vitro by human colon adenocarcinoma Caco-2 cells, also suggesting a low oral bioavailability. The oral bioavailability of FB₁ in chickens is only 0.7% [36]. In contrast, for HFB₁ a high transcellular passage has been observed in vitro, particularly from the basolateral to the apical side, suggesting that HFB₁ is effluxed by P-gp [33,37]. Remarkably, this P-gp transport mechanism was upregulated following exposure to the toxic FBs parent molecules, which could affect the TK properties of the HFB₁ metabolite, as it is a P-gp substrate. Since exposure to HFB₁ is linked with the hydrolysis of FB₁ by intestinal enzymes or by a feed additive enzyme, the aim of this study was to investigate not only the TK parameters of HFB₁ alone, but also the impact of prior exposure to FBs on these parameters.

2. Results and Discussion

During the animal experiment, no signs of illness due to FBs or HFB₁ toxicity were observed in any of the broiler chickens. All birds were alert, showed a normal feed intake and normal droppings, and no regurgitation was observed. The average bodyweight (BW) was similar ($p = 0.820$) in both groups (control and FBs diet), 974 ± 109 and 1036 ± 110 g at day 21, respectively. This matched expectations, since the contaminated feed contained 10.8 mg FB₁, 3.3 mg FB₂ and 1.5 mg FB₃/kg feed, and therefore approached, but was below, the EU guidance level of 20 mg FB₁ + FB₂/kg [19].

Additionally, HFB₁ is generally known to be less toxic than its parent toxin FB₁ [26,27], and poultry species are known to be able to tolerate high doses of FB₁, especially regarding performance response, with no effect on growth of broiler chickens up to 75–100 mg FB₁/kg feed [15].

To the authors' knowledge, for the first time, the TK properties of HFB₁ were determined in broiler chickens, both after feeding a control and FBs-contaminated diet. In pigs, biotransformation of FB₁ into pHFB₁, and further to HFB₁, by their digestive microbiota and liver has been observed after being fed an FBs-contaminated diet containing 45 mg FB₁, 8.6 mg FB₂ and 4.6 mg FB₃/kg for 10 days, together with a persistence of low levels of pHFB₁ in most organs for several days [30]. However, only low concentrations of pHFB_{1a} and pHFB_{1b} have been detected in the plasma of broiler chickens, fed an FBs-contaminated diet with 10 mg FBs/kg for 14 days [28]. The formation of pHFB_{1a}, pHFB_{1b} and HFB₁ after FB₁ exposure has been described in turkeys [32], monkeys [29] and rats [31] as well. Accordingly, in this study, only traces (> limit of quantification; LOQ) of pHFB_{1b} (0.94–1.34 ng/mL and 0.93–2.43 ng/mL, respectively) were detected in a few samples of broiler chickens fed the FBs-contaminated diet, and subsequently administered an IV or PO bolus of HFB₁, respectively. Although, the presence of pHFB_{1a} was detected in some samples of broilers fed the FBs-contaminated diet (> limit of detection; LOD), it could not be quantified (<LOQ). No pHFB_{1a} or pHFB_{1b} was detected in chickens fed the control diet. Low levels of FB₁ were observed in chickens fed the FBs-contaminated diet, with average background levels at all timepoints of 4.89 ± 5.91 ng/mL and 2.67 ± 3.70 ng/mL, in broiler chickens administered HFB₁ IV and PO, respectively. No FB₁ was detected in the plasma of animals fed the control diet. Consequently, it can be concluded that the observed pHFB₁ in the plasma of animals fed the FBs-contaminated diet resulted from hydrolysis of the FB₁ present in the diet. However, the intestinal microbiota of broiler chickens and turkeys seems to have a rather limited capacity to hydrolyze FBs [28,32]. HFB₁ initiated lesser inflammatory responses than FB₁ in an in vitro co-culture model of porcine intestinal epithelial and immune cells [38]. In vivo toxicity of the intermediate, pHFB₁, has only been investigated in rats so far, resulting in no observed in vivo toxicity [31]. On the other hand, hepatic and renal lesions, in terms of single-cell necrosis, mitosis, apparent collapse of the centrilobular parenchyma of the liver and single-cell necrosis of the outer medulla, and cytoplasmic vacuolation of the kidney, have been reported in rats fed nixtamalized feed containing HFB₁ [39], while no hepatotoxicity or pathological changes of the liver, brain, heart, kidneys, thymus or mesenteric lymph nodes examined in mice fed purified HFB₁ have been detected [40]. This different outcome could probably be explained by the presence of residual, partially hydrolyzed or masked FB₁, following the process of nixtamalization [5]. However, no significant influence of HFB₁ on the intestinal lesion score of the villi morphology in piglets exposed to HFB₁ has been observed [41].

No N-acyl or phase II metabolites of HFB₁ were detected in any of the samples in this study. N-acyl-metabolites of HFB₁ were highly cytotoxic in human colonic HT29 cells, and were also characterized as a potent inhibitor of ceramide synthase [34]. HFB₁ acylation has been evaluated in rats, and although N-acyl-metabolites were detected, no toxicity was observed in vivo [5]. While N-acylation of FB₁ and HFB₁ occurred in human cell lines and in rats [33,34], the occurrence of these metabolites in avian species has not yet been observed, matching the absence of these metabolites in this study.

Comparative HFB₁ plasma concentration–time profiles, following IV HFB₁ administration to broiler chickens fed either a control diet or a FBs-contaminated diet, are shown in Figure 2. Visual inspection of the goodness-of-fit plots of the individual, model-predicted concentrations (IPRED) versus the observed HFB₁ plasma concentrations (C_{obs}) revealed an appropriate structural model for most individuals (Figure S1A). The QQ-plots of the conditionally weighted residuals of C_{obs} demonstrated the normal distribution of the weighted residuals (Figure S1B). The addition of the covariate experimental diet (control versus FBs-contaminated) did not significantly improve the -2 log likelihood-ratio (2LL) of any of the fixed effect parameters' volume of distribution of the central compartment (V_c), volume of distribution of the peripheral compartment (V_p), total body clearance (Cl), or intercompartmental flow (Q), and was therefore not retained in the final model.




Figure 2. Comparative plasma concentration–time profile of HFB₁ after intravenous (IV) administration of 1.25 mg HFB₁/kg bodyweight to broiler chickens fed either a control diet ($n = 8$) or a fumonisins (FBs)-contaminated diet (10.8 mg FB₁, 3.3 mg FB₂ and 1.5 mg FB₃/kg feed, $n = 8$) for two weeks. Values are presented as mean + standard deviation (SD).

The toxicokinetic parameters of HFB₁ following IV administration are shown in Table 1, and are described by a two-compartment model. The mean plasma concentration of HFB₁ in broiler chickens fed an FBs-contaminated diet for 2 weeks following IV administration (plasma concentration at time 0; C_0) was 339.59 ng/mL. The total exposure of HFB₁ in broiler chickens after IV administration, from timepoint 0 to infinity (area under the plasma-concentration time curve from time 0 to infinity; $AUC_{0-\infty}$), was 76.26 ng·h/mL. Regarding volume of distribution (V_d), values of 3.68 L/kg and 5.04 L/kg have been determined for the central and peripheral compartments, respectively, thus resulting in a V_d of 8.7 L/kg at steady state (V_{ss}). Accordingly, pigs given a single HFB₁ IV bolus showed a V_d of 11.0 L/kg, in a one-compartmental model [42]. Furthermore, a short distribution half-life ($T_{1/2\alpha}$) of 0.09 h, followed by a longer elimination half-life ($T_{1/2\beta}$) of 0.69 h, was revealed. In barrows given a single IV bolus, of 0.056 mg/kg BW, of HFB₁, a $T_{1/2\alpha}$ of 0.05 h and a $T_{1/2\beta}$ of 1.01 ± 0.80 h was observed [42]. The mean residence time (MRT) of HFB₁ after IV administration to broiler chickens was 0.53 h, and the elimination rate constant (k_e) was 4.4 h^{-1} . In comparison to pigs, with a total body clearance of 6.7 L·kg/h in barrows after IV HFB₁ administration, broilers seem to have a higher total body clearance (16.39 L/kg·h). The latter could concur with the oral bioavailability of parental FB₁ being higher in swine than in poultry, with values of 3.1% [42] and 0.7% [36], respectively, and with poultry being rather resistant to FBs toxicity when compared to pigs or other mammals [13–18].

Table 1. Population toxicokinetic results of intravenous (IV) administration of HFB₁ (1.25 mg/kg BW) to broiler chickens [$n = 16$, 8 animals fed a control diet and 8 animals fed a fumonisins (FBs)-contaminated diet prior HFB₁ administration].

Θ	Tv θ	CV (%)	ω
V _c (L/kg)	3.68	23.47	0.095
V _p (L/kg)	5.04	41.47	0.009
V _{ss} (L/kg)	8.72	28.75	/
Cl (L/kg·h)	16.39	12.67	0.126
Q (L/kg·h)	8.34	41.37	0.391
AUC _{0-inf} (ng·h/mL)	76.26	12.67	/
C ₀ (ng/mL)	339.59	23.47	/
K _e (1/h)	4.45	26.27	/
MRT (h)	0.53	31.56	/
T _{1/2α} (h)	0.09	33.26	/
T _{1/2β} (h)	0.69	40.41	/

Θ : fixed effect parameter; Tv θ : population typical value of the fixed effect parameter; CV: coefficient of variation; ω : variance of the interindividual variability (only for fixed parameters). Addition of the covariate experimental diet (control versus FBs-contaminated) did not significantly improve the -2 log likelihood ($-2LL$) of any of the fixed effect parameters, and was therefore not retained in the final model. V_c: volume of distribution of the central compartment; V_p: volume of distribution of the peripheral compartment; V_{ss}: volume of distribution at steady state; Cl: total body clearance; Q: intercompartmental flow, AUC_{0-inf}: area under the plasma concentration–time curve from time 0 to infinity; C₀: plasma concentration at time 0 following IV administration; K_e: elimination rate constant; MRT: mean residence time; T_{1/2 α} : distribution half-life, and T_{1/2 β} : elimination half-life.

Plasma concentrations of HFB₁ after oral administration were only above the LOQ in a limited number of samples, and are shown in Figure 3. Consequently, no TK modelling could be performed on these data. Still, the rather fast appearance of HFB₁ in the systemic circulation after oral administration indicates that the ingested mycotoxin is mainly absorbed in the proximal part of the small intestines.




Figure 3. Comparative plasma concentration–time profiles of HFB₁ after oral (PO) administration of 1.25 mg HFB₁/kg bodyweight to broiler chickens fed either a control diet ($n = 8$) or a fumonisins (FBs)-contaminated diet (10.8 mg FB₁, 3.3 mg FB₂ and 1.5 mg FB₃/kg feed, $n = 8$) for two weeks. Values are presented as means + standard deviatie (SD).

The T_{max} of HFB₁ (10 min) after oral HFB₁ administration in the FBs-fed group was reached remarkably fast, when compared to studies of oral FB₁ intake in laying hens, turkeys and ducks, where respective T_{max} values of 60 min, 180 min and 60–120 min were observed [43].

Previously, a disturbance of intestinal homeostasis of chickens fed an FBs-contaminated diet (18.6 mg FB₁+FB₂/kg feed) was demonstrated [21]. In another study, broiler chickens were either fed an FBs-contaminated (8.70 mg FB₁/kg, 4.15 mg FB₂/ kg and 1.44 mg FB₃/kg feed) or a control diet, resulting in FB₁ influencing the expression of intestinal P-gp [24]. With HFB₁ being a substrate of this receptor [24], another aim of this research was to examine whether prolonged FB₁ exposure would influence the uptake of its metabolite HFB₁ in the intestines of broiler chickens. Regarding the difference in plasma concentrations between the FBs and the control diet fed groups, after oral administration of HFB₁, in this study, one could presume that a prolonged FBs exposure actually does influence the intestinal uptake of HFB₁. But as mentioned before, the quantity of plasma concentration measurements above the LOQ, after oral HFB₁ administration, was insufficient to allow the drawing of conclusions from those results. The latter is also held responsible for the fact that no calculation of oral bioavailability of HFB₁ could be made. Nevertheless, a high transcellular passage, particularly from the basolateral to the apical side, was revealed for HFB₁ in human colon adenocarcinoma Caco-2 cells, suggesting that HFB₁ is effluxed by P-gp [33,37]. Since an increased expression of multi-drug resistance protein 1 (MDR1), encoding for P-gp, could be observed in the intestine of broiler chickens fed an FBs-contaminated diet [24], oral bioavailability of HFB₁ could vary, leaving one with the need for more research on the oral bioavailability of HFB₁ in avian species. In broiler chickens, the oral bioavailability of FB₁, being mainly negatively charged in the duodenum and jejunum due to the pH which therefore limits oral absorption by passive non-ionic transcellular diffusion [43], is known to be rather low [44]. Similarly, in this study only very low plasma levels of HFB₁ were detected in broiler chickens following oral administration, suggesting a very low oral bioavailability. That said, in rats, the bioavailability of HFB₁ was thought to be greater than that of FB₁, since about 2.5-fold greater amounts of ¹⁴C-HFB₁, compared to ¹⁴C-FB₁, were excreted in urine after oral administration of 0.69 μmol ¹⁴C-FB₁ and ¹⁴C-hydrolyzed FB₁/kg BW [45], increasing the likelihood that HFB₁ can be absorbed by the gut, and in the meantime allowing the subsequent metabolism of N-acyl-HFB₁ and the enhancing of its possible toxicological effects.

3. Conclusions

While HFB₁ is shown to be less toxic than its parental toxin FB₁, its toxicokinetic pathways in avian species are still widely unexplored. In this study, toxicokinetic parameters following administration of a single IV bolus of HFB₁ to broiler chickens have been determined (V_c , V_p , V_{ss} , Cl , Q , AUC_{0-inf} , C_0 , k_e , MRT , $T_{1/2\alpha}$ and $T_{1/2\beta}$). The plasma concentrations of HFB₁ after oral administration were only above the LOQ in a limited number of samples. Consequently, no TK modelling could be performed on these data. Traces of pHFB_{1b} (0.94–1.34 ng/mL and 0.93–2.43 ng/mL, respectively) have been detected in a few samples of broiler chickens fed the FBs-contaminated diet, and subsequently administered an IV bolus or PO bolus of HFB₁, respectively. Using UPLC-HRMS, no phase II metabolites or N-acyl metabolites of HFB₁ could be detected in any of the samples.

4. Materials and Methods

4.1. HFB₁ for Animal Trial

HFB₁ for oral (PO) and intravenous (IV) administration was prepared as previously described [31] with some minor changes. HFB₁ for PO administration was obtained by enzymatic treatment of *F. verticillioides* culture material with the FB carboxylesterase FumD (80 U enzyme/g culture material) for 30 min, and subsequently purified and lyophilized [31]. Per 250 g of culture material, 2550 μmol HFB₁ was obtained.

HFB₁ for IV administration was prepared by alkaline hydrolysis of FB₁ analytical standard (Biopure, Tulln, Austria). Therefore, 5 mL of FB₁ solution (7.4 mg/mL water) was hydrolyzed with 4 mL of 2.5M NaOH by shaking for 7.5 h. After completing the conversion, the formed HFB₁ was

recovered by liquid–liquid extraction (eight times with acetonitrile (ACN)). The achieved HFB₁ solution was purified over an SPE C18 column to remove salts and tricarballic acids, and subsequently diluted in a 0.9% NaCl solution up to a concentration of 4.18 mg HFB₁/mL, with traces of pHFB_{1a} (0.0045 mg/mL). HFB₁ for PO and IV administration was stored at 2–8 °C.

4.2. Feed Preparation and Experimental Diets

A commercial broiler starter diet was fed to all chickens (Vanden Avenne, Ooigem, Belgium) during the first week of the experiment. Later, this diet is referred to as control diet. From day 8 until day 24 chickens were fed either the control diet without mycotoxins [commercial broiler grower diet (Vanden Avenne)], or a grower diet experimentally contaminated with FBs. None of the diets contained a mycotoxin detoxifier. Screening of the control starter and grower feeds for mycotoxin contamination was executed by a liquid chromatography tandem mass spectrometer (LC-MS/MS) method, as described by Monbaliu et al. [46]. The levels of all tested mycotoxins were below the decision limit (CC α) in the control starter and grower diets. More specifically, the CC α values of FB₁, FB₂ and FB₃ were 58, 45 and 42 μ g/kg feed, respectively.

To produce the grower diet experimentally contaminated with FBs, FBs culture material was mixed with 500 g of control feed. Lyophilized FBs culture material of *F. verticillioides* (M-3125) [47] (7.37 g FB₁/g and 2.93 g FB₂/g) was obtained from Biopure, Romer Labs Diagnostic GmbH (Tulln, Austria) and stored at 2–8 °C. This premix was then blended with 5 kg of control feed to ensure a homogeneous distribution of the mycotoxins. The premix was blended for 20 min into the total quantity of feed necessary for the trial. To test the homogeneity of FBs in feed, samples were taken at three different points in the batch and analyzed for FBs as described for the control diets. The FBs-contaminated diet contained 10.8 mg FB₁, 3.3 mg FB₂ and 1.5 mg FB₃/kg feed.

4.3. Animal Experiment

A total of 16 one-day-old broiler chickens (Ross 308) were obtained from a commercial hatchery (Vervaeke-Belavi, Tielt, Belgium), and were fed a starter diet without mycotoxins during the first week. Subsequently, animals were randomly divided into two experimental groups of eight animals (4 male/4 female). While one group was being fed a control grower diet from day 8 onwards, the other group was given a FBs-contaminated grower diet. An 18 h/6 h light/darkness program was applied. Feed and drinking water were provided ad libitum.

A toxicokinetic (TK) study of HFB₁ was performed following a two-way cross-over design. Each broiler chicken was administered a bolus of HFB₁ (1.25 mg/kg bodyweight) either orally (PO) or intravenously (IV) (vena cutanea ulnaris superficialis or wing vein). At day 21, four chickens of each group were administered HFB₁ IV, and the four other animals received HFB₁ PO. After a wash out and recovery period of two days, the protocol was repeated at day 24 in a cross-over design. Animals were feed-deprived overnight (8 h) prior to, and until 3 h after, HFB₁ administration. After each bolus dosing, blood was collected into heparinized tubes by direct venipuncture of the leg vein (vena metatarsalis plantaris superficialis) before (0 h) and at different time points after HFB₁ administration: 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h and 9 h post-administration (p.a.). Blood samples were centrifuged (2851 \times g, 10 min, 4 °C) and plasma was stored at \leq -15 °C until analysis.

The animal experiment was approved by the Ethical Committee of the Faculty of Veterinary Medicine and the Faculty of Bioscience Engineering of Ghent University (EC 2015/10, approval date: 9 March 2015).

4.4. Plasma Fumonisin Analysis: FB₁, FB₂, FB₃, HFB₁, pHFB_{1a}, pHFB_{1b}, Phase II Metabolites and N-Acyl Metabolites

FB₁, and its partially hydrolyzed metabolites pHFB_{1a + b} and hydrolyzed metabolite HFB₁, in plasma, were determined using a validated sensitive and specific UPLC-MS/MS method as described by De Baere et al. (2018) [48].

4.4.1. Preparation of Standard Solutions

Stock solutions of FB₁, FB₂ and FB₃ (1 mg/mL) were made in water/ACN (50/50, *v/v*) and kept at 2–8 °C. Working solutions of 10 µg/mL, 1 µg/mL and 0.1 µg/mL were made by adequate dilution of the stock solution in water/ACN (50/50, *v/v*). The standard mixture solution contained FB₁, HFB₁, pHFB_{1a} and pHFB_{1b} and was adequately diluted in water/ACN (50/50, *v/v*) in order to prepare working solutions necessary for the preparation of calibrator and quality control (QC) samples. A working solution of 1 µg/mL of ¹³C₃₄-FB₁ was made in water/ACN (50/50, *v/v*) to obtain the internal standard (IS). All working solutions were kept at 2–8 °C.

4.4.2. Plasma Sample Pre-Treatment

To 100 µL of plasma 12.5 µL of the IS working solution (1 µg/mL) was added. Then, after vortex mixing the sample was transferred onto an Ostro™ 96-well plate. Next, 300 µL of 1% formic acid (FA) in ACN was added, after which the sample was aspirated 3 times in order to stimulate protein precipitation. By the application of a vacuum (67.7 kPa) for 10 min, the sample was run through the 96-well plate. An aliquot of 2.5-µL was injected onto the LC-MS/MS instrument.

4.4.3. UPLC-MS/MS Method for Quantification

Briefly, the LC system was composed of an Acquity UPLC H-Class Quaternary Solvent Manager and Flow-Through-Needle Sample Manager with temperature-controlled tray and column oven from Waters (Zellik, Belgium). Chromatographic separation was accomplished on an Acquity UPLC HSS T3 column (100 mm × 2.1 mm i.d., dp: 1.8 µm) (Waters, Zellik, Belgium) combined with an Acquity HSS T3 1.8 µm Vanguard pre-column (Waters, Zellik, Belgium). The mobile phase A was composed of 0.3% FA and 10 mM NH₄FA in water, and the mobile phase B was ACN. A gradient elution of 0–0.5 min (90% A, 10% B), 5.5 min (linear gradient to 90% B), 5.5–7.5 min (10% A, 90% B), 7.7 min (linear gradient to 90% A) and 7.7–10.0 min (90% A, 10% B) was performed. The flow-rate was set at 0.4 mL/min. The temperatures of the column oven and autosampler tray were adjusted to 40 °C and 8 °C, respectively. The UPLC column effluent was coupled to a Xevo TQ-S® MS/MS system, supplied with a positive electrospray ionization (ESI) probe (all from Waters). A divert valve was utilized and the UPLC effluent was routed to the mass spectrometer from 2.5 to 4.5 min. Optimization of instrument parameters was obtained by directly infusing working solutions of 1 µg/mL of FB₁, FB₂, FB₃, the IS and a diluted standard mixture solution, which contained FB₁, HFB₁, pHFB_{1a} and pHFB_{1b} at concentrations of 0.5, 0.86, 1.43 and 2.5 µg/mL, respectively, combined with the mobile phase (50% A, 50% B, flow-rate: 200 µL/min). The flow-rate was set at 10 µL/min. MS/MS acquisition was operated in the multiple reaction monitoring (MRM) mode [48].

4.4.4. UPLC-HR-MS Analysis for Identification

To determine potential HFB₁ phase II and N-acyl metabolites in plasma samples of broiler chickens, an Acquity I-Class UPLC interfaced to a Synapt G2-Si HDMS instrument (Waters, Zellik, Belgium) was used [48].

4.5. Toxicokinetic Modelling

Plasma concentration–time data were analyzed with a nonlinear mixed-effects modelling approach using quasi-random parametric expectation maximization (QRPEM) as an estimation method in Phoenix NLME® (Certara, Cary, NC, USA). The structural toxicokinetic model for the IV data was a two-compartmental model with first order elimination as shown in Equation 1.

$$\begin{aligned} (dA_1/dt) \times 1/V_c &= -Cl \times C - Q \times (C - C_2) \\ (dA_2/dt) \times 1/V_p &= Q \times (C - C_2) \end{aligned} \quad (1)$$

Where dA_1/dt is the rate of the decrease of the amount of mycotoxin in the plasma or central compartment, dA_2/dt is the rate of decrease of the amount of mycotoxin in the peripheral compartment, V_c is the volume of distribution of the central compartment, V_p is the volume of

distribution of the peripheral compartment, Cl is total body clearance, Q is the intercompartmental flow and C and C_2 are the concentrations of the toxin in the central and peripheral compartments, respectively.

Interindividual variability was expressed using an exponential error model according to Equation 2:

$$P_i = \theta_P \times e^{\eta_{Pi}} \quad (2)$$

where P_i is the parameter in the i^{th} bird, θ_P is the typical value of the parameter in the population, and η_{Pi} is a random variable in the i^{th} bird, with a mean of zero and a variance of ω^2 . Interindividual variability is reported as ω . Residual variability (ϵ), with a mean of zero and a variance of σ^2 , was best described with a multiplicative error model in Equation 3.

$$C_{\text{obs}} = C_{\text{pred}} \times (1 + \epsilon) \quad (3)$$

where C_{obs} is the observed concentration for the individual and C_{pred} is the model-predicted concentration plus the error value (ϵ).

Structural and error model selection was guided by visual inspection of goodness-of-fit plots (e.g., observed vs predicted plasma concentrations, weighted residuals versus predicted concentrations, and weighted residuals versus time), $-2LL$, Akaike information criterion (AIC) and Bayesian information criterion (BIC) as well as precision of the parameter estimates. The models were chosen based on the smaller values of $-2LL$, AIC and BIC, the better precision of estimates, and the superior goodness-of-fit plots.

The evaluated covariate was the prior feeding with FBs-contaminated feed versus feeding with uncontaminated control feed (categorical variable). A stepwise forward-backward process was used to evaluate whether inclusion of the covariates significantly improved the model fit using a $-2LL$ test. A decrease in $-2LL$ with a p -value < 0.01 was considered significant for addition, and $p < 0.001$ for exclusion, of the covariate.

The following fixed effect parameters were determined: V_c , V_p , Cl and Q . The computed secondary parameters were: C_0 , $AUC_{0-\text{inf}}$, K_e , MRT , $T_{1/2\alpha}$ and $T_{1/2\beta}$.

Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/12/6/413/s1, Figure S1: Visual evaluation of the population model of HFB₁ after intravenous (IV) dosing: scatter plot of the population dependent variable (DV), namely observed plasma concentration (C_{obs}), versus the individually predicted plasma concentration values (IPRED) (A) and QQ plot of the conditionally weighted residuals of C_{obs} (B).

Author Contributions: G.A., S.D.B. and S.C. conceived and designed the experiments; G.A. performed the animal experiment; S.D.B. performed the analytical experiments; B.N. and D.S. contributed to the synthesis of the FB₁, pHFB_{1a}, pHFB_{1b} and HFB₁ standard mixture; G.A., S.D.B. and M.D. analyzed the data; G.A., S.D.B. and D.d.H. drafted the manuscript. All authors read and approved the final version of the manuscript.

Funding: This research was funded supported by BIOMIN Holding GmbH, Austria.

Acknowledgments: The technical assistance of J. Muyle was gratefully appreciated. M. Eeckhout and M. Van Hecke from the Department of Applied Biosciences, Faculty of Bioscience Engineering, Ghent University are acknowledged for the preparation of the experimental diets. S. De Saeger and C. Detavernier from the Centre of Excellence in Mycotoxicology & Public Health, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, are acknowledged for the mycotoxin analyses of the feed samples. The authors gratefully appreciated the excellent assistance of many PhD students from the Department of Pharmacology, Toxicology and Biochemistry. G. Bichl of BIOMIN Holding GmbH is also greatly acknowledges for her help contributing this research. G. Antonissen was supported by a postdoctoral fellowship from Research Foundation—Flanders (12V6418N). The Laboratory of Pharmacology and Toxicology is part of the Ghent University expertise centre MSmall. The authors acknowledge the Hercules Synpat G2-Si HDMS instrument infrastructure funding AUGE/13/13.

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Gelderblom, W.C.; Jaskiewicz, K.; Marasas, W.F.; Thiel, P.G.; Horak, R.M.; Vlegaar, R.; Kriek, N.P. Fumonisin-novel mycotoxins with cancer-promoting activity produced by *Fusarium moniliforme*. *Appl. Environ. Microbiol.* **1988**, *54*, 1806–1811, doi:10.1128/aem.54.7.1806-1811.1988.
2. Voss, K.; Smith, G.; Haschek, W. Fumonisin: Toxicokinetics, mechanism of action and toxicity. *Anim. Feed. Sci. Technol.* **2007**, *137*, 299–325, doi:10.1016/j.anifeedsci.2007.06.007.
3. Humpf, H.-U.; Voss, K.A. Effects of thermal food processing on the chemical structure and toxicity of fumonisin mycotoxins. *Mol. Nutr. Food Res.* **2004**, *48*, 255–269, doi:10.1002/mnfr.200400033.
4. Stockmann-Juvala, H.; Savolainen, K. A review of the toxic effects and mechanisms of action of fumonisin B1. *Hum. Exp. Toxicol.* **2008**, *27*, 799–809, doi:10.1177/0960327108099525.
5. Seiferlein, M.; Humpf, H.-U.; Voss, K.A.; Sullards, M.C.; Allegood, J.C.; Wang, E.; Merrill, A.H. Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites. *Mol. Nutr. Food Res.* **2007**, *51*, 1120–1130, doi:10.1002/mnfr.200700118.
6. Merrill, A.H.; Sullards, M.C.; Wang, E.; Voss, K.A.; Riley, R.T. Sphingolipid metabolism: Roles in signal transduction and disruption by fumonisins. *Environ. Health Perspect.* **2001**, *109*, 283–289.
7. Riley, R.T.; Enongene, E.; Voss, K.A.; Norred, W.P.; Meredith, F.I.; Sharma, R.P.; Spitsbergen, J.; Williams, D.E.; Carlson, D.B.; Merrill, A.H. Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis. *Environ. Health Perspect.* **2001**, *109*, 301–308.
8. Wang, E.; Norred, W.P.; Bacon, C.W.; Riley, R.T.; Merrill, A.H. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with *Fusarium moniliforme*. *J. Biol. Chem.* **1991**, *266*, 14486–14490.
9. Benlasher, E.; Geng, X.; Nguyen, N.T.X.; Tardieu, D.; Bailly, J.-D.; Auvergne, A.; Guerre, P. Comparative Effects of Fumonisin on Sphingolipid Metabolism and Toxicity in Ducks and Turkeys. *Avian Dis.* **2012**, *56*, 120–127, doi:10.1637/9853-071911-reg.1.
10. Qiu, M.; Liu, X. Determination of sphinganine, sphingosine and Sa/So ratio in urine of humans exposed to dietary fumonisin B1. *Food Addit. Contam.* **2001**, *18*, 263–269, doi:10.1080/02652030117470.
11. Bouhet, S.; Oswald, I.P. The intestine as a possible target for fumonisin toxicity. *Mol. Nutr. Food Res.* **2007**, *51*, 925–931, doi:10.1002/mnfr.200600266.
12. Grenier, B.; Applegate, T. Modulation of Intestinal Functions Following Mycotoxin Ingestion: Meta-Analysis of Published Experiments in Animals. *Toxins* **2013**, *5*, 396–430, doi:10.3390/toxins5020396.
13. Javed, T.; Bennett, G.A.; Richard, J.L.; Dombrink-Kurtzman, M.A.; Côté, L.M.; Buck, W.B. Mortality in broiler chicks on feed amended with *Fusarium proliferatum* culture material or with purified fumonisin B1 and moniliformin. *Mycopathologia* **1993**, *123*, 171–184, doi:10.1007/bf01111269.
14. Kubena, L.; Harvey, R.; Buckley, S.; Bailey, R.; Rottinghaus, G. Effects of long-term feeding of diets containing moniliformin, supplied by *Fusarium fujikuroi* culture material, and fumonisin, supplied by *Fusarium moniliforme* culture material, to laying hens. *Poult. Sci.* **1999**, *78*, 1499–1505, doi:10.1093/ps/78.11.1499.
15. le Doux, D.R.; Brown, T.P.; Weibking, T.S.; Rottinghaus, G. Fumonisin Toxicity in Broiler Chicks. *J. Veter. Diagn. Investig.* **1992**, *4*, 330–333, doi:10.1177/104063879200400317.
16. Tardieu, D.; Bailly, J.D.; Benard, G.; Tran, T.S.; Guerre, P. Toxicity of maize containing known levels of fumonisin B1 during force-feeding of ducks. *Poult. Sci.* **2004**, *83*, 1287–1293, doi:10.1093/ps/83.8.1287.
17. Tran, S.T.; Auvergne, A.; Benard, G.; Bailly, J.D.; Tardieu, D.; Babile, R.; Guerre, P. Chronic effects of fumonisin B1 on ducks. *Poult. Sci.* **2005**, *84*, 22–28, doi:10.1093/ps/84.1.22.
18. Weibking, T.S.; le Doux, D.R.; Bermudez, A.J.; Turk, J.R.; Rottinghaus, G.E.; Wang, E.; Merrill, A.H. Effects of Feeding *Fusarium moniliforme* Culture Material, Containing Known Levels of Fumonisin B1, on the Young Broiler Chick. *Poult. Sci.* **1993**, *72*, 456–466, doi:10.3382/ps.0720456.
19. Commission of the European Communities Commission recommendation 2006/576/ec of 17 August 2007 on the presence of deoxynivalenol, zearalenone, ochratoxin A, T-2 and HT-2 and fumonisins in products. *Off. J. Eur. Union* **2006**, *229*, 7–9.
20. Antonissen, G.; Martel, A.; Pasmans, F.; Ducatelle, R.; Verbrugghe, E.; Vandenbroucke, V.; Li, S.; Haesebrouck, F.; van Immerseel, F.; Croubels, S. The Impact of *Fusarium* Mycotoxins on Human and Animal Host Susceptibility to Infectious Diseases. *Toxins* **2014**, *6*, 430–452, doi:10.3390/toxins6020430.

21. Antonissen, G.; Croubels, S.; Pasmans, F.; Ducatelle, R.; Eeckhaut, V.; Devreese, M.; Verlinden, M.; Haesebrouck, F.; Eeckhout, M.; de Saeger, S.; et al. Fumonisin affect the intestinal microbial homeostasis in broiler chickens, predisposing to necrotic enteritis. *Veter Res.* **2015**, *46*, 98, doi:10.1186/s13567-015-0234-8.
22. Antonissen, G.; van Immerseel, F.; Pasmans, F.; Ducatelle, R.; Janssens, G.P.J.; de Baere, S.; Mountzouris, K.; Su, S.; Wong, E.A.; de Meulenaer, B.; et al. Mycotoxins Deoxynivalenol and Fumonisin Alter the Extrinsic Component of Intestinal Barrier in Broiler Chickens. *J. Agric. Food Chem.* **2015**, *63*, 10846–10855, doi:10.1021/acs.jafc.5b04119.
23. Grenier, B.; Schwartz-Zimmermann, H.E.; Caha, S.; Moll, W.-D.; Schatzmayr, G.; Applegate, T. Dose-Dependent Effects on Sphingoid Bases and Cytokines in Chickens Fed Diets Prepared with *Fusarium Verticillioides* Culture Material Containing Fumonisin. *Toxins* **2015**, *7*, 1253–1272, doi:10.3390/toxins7041253.
24. Antonissen, G.; Devreese, M.; de Baere, S.; Martel, A.; van Immerseel, F.; Croubels, S. Impact of *Fusarium* mycotoxins on hepatic and intestinal mRNA expression of cytochrome P450 enzymes and drug transporters, and on the pharmacokinetics of oral enrofloxacin in broiler chickens. *Food Chem. Toxicol.* **2017**, *101*, 75–83, doi:10.1016/j.fct.2017.01.006.
25. Bryden, W. Mycotoxin contamination of the feed supply chain: Implications for animal productivity and feed security. *Anim. Feed. Sci. Technol.* **2012**, *173*, 134–158, doi:10.1016/j.anifeedsci.2011.12.014.
26. Heinel, S.; Hartinger, D.; Thamhesl, M.; Vekiru, E.; Krška, R.; Schatzmayr, G.; Moll, W.-D.; Grabherr, R. Degradation of fumonisin B1 by the consecutive action of two bacterial enzymes. *J. Biotechnol.* **2010**, *145*, 120–129, doi:10.1016/j.jbiotec.2009.11.004.
27. Hartinger, D.; Moll, W.-D. Fumonisin elimination and prospects for detoxification by enzymatic transformation. *World Mycotoxin J.* **2011**, *4*, 271–283, doi:10.3920/wmj2011.1285.
28. Grenier, B.; Schwartz-Zimmermann, H.; Gruber-Dorninger, C.; Dohnal, I.; Aleschko, M.; Schatzmayr, G.; Moll, W.-D.; Applegate, T.J. Enzymatic hydrolysis of fumonisin in the gastrointestinal tract of broiler chickens. *Poult. Sci.* **2017**, *96*, 4342–4351, doi:10.3382/ps/pex280.
29. Shephard, G.S.; Thiel, P.; Sydenham, E.; Vleggaar, R.; Alberts, J. Determination of the mycotoxin fumonisin B1 and identification of its partially hydrolysed metabolites in the faeces of non-human primates. *Food Chem. Toxicol.* **1994**, *32*, 23–29, doi:10.1016/0278-6915(84)90032-2.
30. Fodor, J.; Balogh, K.; Weber, M.; Mézes, M.; Kametler, L.; Pósa, R.; Mamet, R.; Bauer, J.; Horn, P.; Kovács, F.; et al. Absorption, distribution and elimination of fumonisin B1 metabolites in weaned piglets. *Food Addit. Contam. Part A* **2007**, *25*, 88–96, doi:10.1080/02652030701546180.
31. Hahn, I.; Nagl, V.; Schwartz-Zimmermann, H.; Varga, E.; Schwarz, C.; Slavik, V.; Reisinger, N.; Malachová, A.; Cirlini, M.; Generotti, S.; et al. Effects of orally administered fumonisin B1 (FB1), partially hydrolysed FB1, hydrolysed FB1 and N-(1-deoxy-D-fructos-1-yl) FB1 on the sphingolipid metabolism in rats. *Food Chem. Toxicol.* **2015**, *76*, 11–18, doi:10.1016/j.fct.2014.11.020.
32. Masching, S.; Naehrer, K.; Schwartz-Zimmermann, H.E.; Sărăndan, M.; Schaumberger, S.; Dohnal, I.; Nagl, V.; Schatzmayr, D. Gastrointestinal Degradation of Fumonisin B1 by Carboxylesterase FumD Prevents Fumonisin Induced Alteration of Sphingolipid Metabolism in Turkey and Swine. *Toxins* **2016**, *8*, 84, doi:10.3390/toxins8030084.
33. Harrer, H.; Humpf, H.-U.; Voss, K. In vivo formation of N-acyl-fumonisin B1. *Mycotoxin Res.* **2014**, *31*, 33–40, doi:10.1007/s12550-014-0211-5.
34. Humpf, H.-U.; Schmelz, E.M.; Meredith, F.I.; Vesper, H.; Vales, T.R.; Wang, E.; Menaldino, D.S.; Liotta, D.C.; Merrill, A.H. Acylation of Naturally Occurring and Synthetic 1-Deoxysphinganine by Ceramide Synthase. *J. Biol. Chem.* **1998**, *273*, 19060–19064, doi:10.1074/jbc.273.30.19060.
35. Hopmans, E.C.; Hauck, C.C.; Hendrich, S.; Murphy, P.A. Excretion of Fumonisin B1, Hydrolyzed Fumonisin B1, and the Fumonisin B1–Fructose Adduct in Rats. *J. Agric. Food Chem.* **1997**, *45*, 2618–2625, doi:10.1021/jf960886j.
36. Vudathala, D.K.; Prelusky, D.B.; Ayroud, M.; Trenholm, H.L.; Miller, J.D. Pharmacokinetic fate and pathological effects of ¹⁴C-fumonisin B1 in laying hens. *Nat. Toxins* **1994**, *2*, 81–88, doi:10.1002/nt.2620020206.
37. Harrer, H.; Laviad, E.L.; Humpf, H.-U.; Futerman, A.H. Identification of N-acyl-fumonisin B1 as new cytotoxic metabolites of fumonisin mycotoxins. *Mol. Nutr. Food Res.* **2012**, *57*, 516–522, doi:10.1002/mnfr.201200465.

38. Gu, M.J.; Han, S.E.; Hwang, K.; Mayer, E.; Reisinger, N.; Schatzmayr, D.; Park, B.-C.; Han, S.H.; Yun, C.-H. Hydrolyzed fumonisin B1 induces less inflammatory responses than fumonisin B1 in the co-culture model of porcine intestinal epithelial and immune cells. *Toxicol. Lett.* **2019**, *305*, 110–116, doi:10.1016/j.toxlet.2019.01.013.
39. Voss, K.A.; Bacon, C.W.; Meredith, F.I.; Norred, W.P. Comparative Subchronic Toxicity Studies of Nixtamalized and Water-extracted Fusarium. *Food Chem. Toxicol.* **1996**, *34*, 623–632.
40. Howard, P.C.; C.Howarda, P.; Coucha, L.H.; Pattonb, R.E.; Eppleyc, R.M.; Doergea, D.R.; Churchwella, M.I.; Marques, M.M.; Okerbergb, C.V. Comparison of the Toxicity of Several Fumonisin Derivatives in a 28-Day Feeding Study with Female B6C3F1 Mice. *Toxicol. Appl. Pharmacol.* **2002**, *185*, 153–165, doi:10.1006/taap.2002.9529.
41. Grenier, B.; Bracarense, A.-P.F.; Schwartz-Zimmermann, H.; Trumel, C.; Cossalter, A.-M.; Schatzmayr, G.; Kolf-Clauw, M.; Moll, W.-D.; Oswald, I.P. The low intestinal and hepatic toxicity of hydrolyzed fumonisin B1 correlates with its inability to alter the metabolism of sphingolipids. *Biochem. Pharmacol.* **2012**, *83*, 1465–1473, doi:10.1016/j.bcp.2012.02.007.
42. Schertz, H.; Kluess, J.; Frahm, J.; Schatzmayr, D.; Dohnal, I.; Bichl, G.; Schwartz-Zimmermann, H.; Breves, G.; Dänicke, S. Oral and Intravenous Fumonisin Exposure in Pigs—A Single-Dose Treatment Experiment Evaluating Toxicokinetics and Detoxification. *Toxins* **2018**, *10*, 150, doi:10.3390/toxins10040150.
43. Antonissen, G.; Devreese, M.; van Immerseel, F.; de Baere, S.; Hessenberger, S.; Martel, A.; Croubels, S. Chronic Exposure to Deoxynivalenol Has No Influence on the Oral Bioavailability of Fumonisin B1 in Broiler Chickens. *Toxins* **2015**, *7*, 560–571, doi:10.3390/toxins7020560.
44. Guerre, P. Fusariotoxins in Avian Species: Toxicokinetics, Metabolism and Persistence in Tissues. *Toxins* **2015**, *7*, 2289–2305, doi:10.3390/toxins7062289.
45. Dantzer, W.R.; Hopper, J.; Mullin, K.; Hendrich, S.; Murphy, P.A. Excretion of ¹⁴C-Fumonisin B1, ¹⁴C-Hydrolyzed Fumonisin B1, and ¹⁴C-Fumonisin B1-Fructose in Rats. *J. Agric. Food Chem.* **1999**, *47*, 4291–4296, doi:10.1021/jf981340v.
46. Monbaliu, S.; van Poucke, C.; Detavernier, C.; Dumoulin, F.; van de Velde, M.; Schoeters, E.; van Dyck, S.; Averkieva, O.; van Peteghem, C.; de Saeger, S. Occurrence of Mycotoxins in Feed as Analyzed by a Multi-Mycotoxin LC-MS/MS Method. *J. Agric. Food Chem.* **2010**, *58*, 66–71, doi:10.1021/jf903859z.
47. Leslie, J.F.; Doe, F.J.; Plattner, R.D.; Shackelford, D.D.; Jonz, J. Fumonisin B1 production and vegetative compatibility of strains from *Gibberella fujikuroi* mating population ?A? (*Fusarium moniliforme*). *Mycopathologia* **1992**, *117*, 37–45, doi:10.1007/bf00497277.
48. de Baere, S.; Croubels, S.; Novak, B.; Bichl, G.; Antonissen, G. Development and Validation of a UPLC-MS/MS and UPLC-HR-MS Method for the Determination of Fumonisin B1 and Its Hydrolysed Metabolites and Fumonisin B2 in Broiler Chicken Plasma. *Toxins* **2018**, *10*, 62, doi:10.3390/toxins10020062.

